Giorgio Gandaglia

Jan 10, 2025 | europeanurology.com | Mattia Longoni |Alberto Briganti |Giorgio Gandaglia |Francesco Montorsi

Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes aUnit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy b“Vita-Salute” San Raffaele University, Milan, Italy Publication History: Accepted January 2, 2025; Published online January 10,...

Jun 2, 2023 | urotoday.com | Giorgio Gandaglia

Giorgio Gandaglia explores the ongoing clinical trials in the field of prostate cancer, from diagnosis to advanced stages of the disease. He begins by discussing the implementation of PET/CT and MRI in diagnosing prostate cancer and the potential benefits of these tools, including the reduction in clinically insignificant detections and biopsies. Gandaglia highlights the role of novel biomarkers in aiding diagnosis.

Feb 9, 2023 | europeanurology.com | Francesco Montorsi |Simone Scuderi |Alberto Briganti |Giorgio Gandaglia

We read with interest the Platinum Opinion by Schilham et al. [] on how advanced imaging modalities might solve the current diagnostic challenges for patients with prostate cancer (PCa). Although we agree with the authors that new imaging techniques will overcome the limitations of conventional approaches and will play a major role soon, some points warrant further attention.

Feb 9, 2023 | europeanurology.com | Francesco Montorsi |Simone Scuderi |Alberto Briganti |Giorgio Gandaglia

We read with interest the editorial by Powell et al. [] questioning the recent approval by the US Food and Drug Administration and the European Medicines Agency of the first oral gonadotropin-releasing hormone (GnRH) antagonist relugolix for the treatment of patients with advanced prostate cancer (PCa) [].